<aside>
This page summarises the most important evidence on IMPALA's impact: clinical outcomes, cost-effectiveness, health workers and caregivers, and the independent assessment in the Rethink Priorities Report. The strongest evidence comes from paediatric studies in Malawi, supported by usability studies, qualitative research and emerging data from other hospitals.
</aside>
<aside> <img src="/icons/first-aid_green.svg" alt="/icons/first-aid_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/meeting_green.svg" alt="/icons/meeting_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/sharing_green.svg" alt="/icons/sharing_green.svg" width="40px" />
</aside>
<aside> <img src="/icons/cash_green.svg" alt="/icons/cash_green.svg" width="40px" />
</aside>
<aside>
</aside>
<aside>
</aside>
The strongest evidence comes from before-and-after studies on paediatric wards in two Malawian hospitals, where IMPALA was associated with lower mortality and fewer critical illness events at low cost per child. Health workers rate IMPALA highly and report spending less time on monitoring. Neonatal results are emerging and mixed, and no randomised trial has been done yet. Rethink Priorities' independent assessment, which heavily discounts the observed effects, still finds IMPALA highly cost-effective.
<aside>
</aside>